Investigating minocycline’s anti-inflammatory role in alveolar macrophages

Simple item page
dc.contributor.advisorShakerley, Nicole
dc.contributor.authorScholl, Erica '23
dc.contributor.committeememberParent, Michelle
dc.contributor.committeememberButler, David
dc.contributor.committeememberJayachandran, Pradeepa
dc.date.accessioned2024-11-07T16:33:20Z
dc.date.available2024-11-07T16:33:20Z
dc.date.issued2023-08
dc.descriptionClick on the Resource Link to find this item in the ACPHS Library catalog
dc.description.abstractMinocycline has been FDA-approved for 50 years and is utilized to treat a wide range of infections. More recently, minocycline has been used to treat several sterile inflammatory conditions due to its non-antimicrobial anti-inflammatory properties. While minocycline is a unique and beneficial therapeutic, its immunomodulatory impact on inflammation during an active infection is not well understood. Elucidating the molecular mechanism of minocycline’s ability to modulate the inflammatory response can lead to the development of novel therapeutic strategies that take advantage of the antibiotic capabilities of minocycline while also protecting the host against post-infection inflammatory tissue damage. We hypothesized that minocycline exerts anti-inflammatory properties that suppress the cytokine production after macrophage activation, altering the host immune response to pathogens and limiting tissue damage. Our data indicates that minocycline is nontoxic to alveolar macrophages even at doses far beyond therapeutic potential. Additionally, pretreatment with minocycline significantly decreased the activation of nuclear factor kappa beta (NF-κB), as well as the secretion of several inflammatory cytokines following treatment with ligands to activate specific toll-like receptors. Total levels of key signaling molecules MyD88 and NF-κB were not altered following minocycline pretreatment, suggesting that minocycline may be altering the activation status within the cascade. Lastly, the pretreatment of macrophages with minocycline appears to have no significant effect on the production of oxidative stress following ligand treatment at 24 hours. Our long-term goal is to identify immunomodulatory mechanisms exerted by minocycline in the presence of an infection, as it could be the key to managing infections by not only eliminating the pathogen but also minimizing host inflammatory tissue damage, which is a driver of poor patient outcomes.
dc.description.urihttps://acphs.on.worldcat.org/oclc/1467227177
dc.format.extent53 pages
dc.identifier.citationScholl E. Investigating minocycline's anti-inflammatory role in alveolar macrophages. Ann Arbor (MI): Proquest LLC; 2023. 53 p.
dc.identifier.thesis30632042
dc.identifier.urihttps://hdl.handle.net/20.500.14303/604
dc.language.isoen_US
dc.publisherProQuest LLC
dc.relation.ispartofAlbany College of Pharmacy and Health Sciences Theses
dc.subjectThis Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). http://rightsstatements.org/vocab/InC/1.0/
dc.titleInvestigating minocycline’s anti-inflammatory role in alveolar macrophages
dc.typeThesis
local.departmentprogramMSMB MS in Molecular Biosciences
Files
Collections
Masters of Science in Molecular Biosciences Theses
Shakerley, Nicole Theses Advised